RSS Alerts

Latest News

  • Monoclonal antibodies in drug and vaccine development
    Monoclonal antibodies (mAbs) are remarkably versatile protein molecules with numerous applications in human health. More than 30 mAb therapeutics have been approved for marketing and approximately 360 mAbs are currently in clinical studies, with 30 in pivotal trials. The indications of these studies are diverse and include autoimmune disorders, solid and hematological cancers, and infectious diseases. In the preclinical arena, understanding mAb interactions with their targets is also vital to vaccine design. This Drug Discovery Today Editor’s Choice newsletter provides timely reviews on the utility of antibodies as therapeutics and approaches to mAb/antigen interaction studies that aid in vaccine development.
  • Drug Discovery Today: May Issue
    The latest issue of Drug Discovery Today is packed full of industry focused research articles, new developments in drug discovery, and expert comment and opinion.
  • Drug Discovery Today: April Issue
    The latest issue of Drug Discovery Today is packed full of industry focused research articles, new developments in drug discovery, and expert comment and opinion.
  • Drug repositioning: a new path to address unmet clinical needs
    Drug repositioning, the process of finding new indications for existing drugs, presents a promising avenue for identifying better and safer treatments without the full cost or time required for de novo drug development. This young discipline has the potential to supplement flagging drug development pipelines, increase patient quality of life, and address areas of concern, such as rare and neglected diseases. In the past five years, government agencies, academic researchers, and the pharmaceutical industry have worked to move drug repositioning from a serendipitous event based on clinical observation, unfocused screening, and ‘happy accidents’ to a comprehensive and rational search for repositioning opportunities.
  • The use of stem cells for drug discovery and organ repair
    Numerous currently incurable human diseases arise from the loss or malfunction of highly specialized cell types that lack the capacity to regenerate due to diseases (e.g. heart attack, stroke), traumas (e.g. spinal cord injuries by accidents) or aging (e.g. blindness due to age-related macular degeneration, glaucoma). Recent advances in stem cell technologies have made regenerative medicine, once seen only in science fiction, a reachable reality. In this newsletter focusing on ‘Stem Cells’, we have solicited four articles to introduce some fundamental concepts of stem cells and review some of their immediate applications for disease modeling, drug discovery and toxicity screening as well as future possible therapies.
view more

Podcasts

  • Evotec strengthens and expands its Alliance Business
    Dr Mark Ashton is Executive Vice President, Business Development of Evotec and is responsible for Evotec's commercial and partnering activities. Prior to assuming responsibility for Business Development in 2005, Dr Ashton held a number of positions within Operations at Evotec: He joined the Company in 1995 as one of the initial employees of the Discovery Division, becoming Department Manager in 2001, Director of Chemistry Services in 2002 and taking over responsibility for Evotec's Discovery Services Division in 2004, where he had responsibility for Evotec's screening, parallel synthesis and medicinal chemistry operations. During his time at Evotec, Dr Ashton has managed a wide range of pharmaceutical and biotechnology related projects, including medicinal chemistry projects, design and synthesis of screening libraries and technology transfer projects and has been involved in the progression of a number of drug candidates into the clinic in numerous therapeutic areas. Dr Ashton has authored and co-authored a number of peer reviewed papers, articles and book chapters in addition to being named on a number of pharmaceutical patents. He is trained as a medicinal chemist. Prior to joining Evotec, Dr Ashton also had spells at ICI Pharmaceuticals and Organon Laboratories. Mark Whittaker is Senior Vice President Drug Discovery at Evotec where he manages a large drug discovery collaboration and the groups of computational chemistry and structural biology. Before joining Evotec in 2001, Mark spent 13 years at British Biotech Pharmaceuticals where he led a number of medicinal chemistry programmes and was latterly Director of Chemistry. At British Biotech, Mark contributed to the discovery and development of six compounds that have progressed into human clinical trials. Before his career at British Biotech, Mark carried out post-doctoral research at the University of Oxford and at York University, Toronto and obtained a D. Phil in Chemistry from the University of York.
  • The Ubiquitin Story
    In this podcast interview with Drug Discovery Today, Nobel Prize winner Professor Aaron Ciechanover will talk about his career, his Nobel Prize-winning discovery of the UPS, and the extraordinary opportunities and challenges for drug discovery in this area.
  • Califf, Behrman and Kramer discuss the Clinical Trials Transformation Initiative.
    Download the Califf, Behrman and Kramer podcast as an mp3 file
  • Dr Brent Vose outlines AstraZeneca's oncology pipeline.
    Download the Dr. Brent Vose podcast as an mp3 file
view more

Webinars

  • The Promise of Epigenetics in Early Stage Drug Discovery
    Epigenetic targets are exciting to drug discovery scientists because they hold great potential across a wide spectrum of therapeutic areas. The field of epigenetics focuses on the investigation of enzymes that alter gene expression through modification of their target substrates, usually through the addition or removal of methyl or acetyl groups. High-throughput assays to identify agents capable of modifying the action of such enzyme targets has, in the past, proven to be challenging due to the relatively small molecular alterations in addition to the possibility of sequential modifications, leading to multiple end products. As such, high-throughput bioassays that allow the direct, concurrent quantification of multiple modification states are attractive. The RapidFire platform enables high-throughput mass spectrometric analysis of native molecules from in vitro reactions by performing on-line desalting in seconds, as opposed to HPLC, which requires minutes. Moreover, the RapidFire system can be connected to any mass spectrometer providing unparalleled versatility in reaction detection.
  • Integrated Quant / Qual for In-vivo Discovery Bioanalysis using Hybrid Quadrupole-Time-of-Flight Mass Spectrometry
    Ultra high performance liquid chromatography (UHPLC) coupled with orthogonal acceleration hybrid quadrupole-time-of-flight (QqTOF) mass spectrometry is an emerging technique offering new strategies for the efficient screening of new chemical entities (NCE) and related molecules at the early discovery stage within the pharmaceutical industry.
  • Drug Delivery: enabling technology for discovery and development
    The integration of pharmacodynamic and pharmacokinetic parameters in non clinical pharmacology studies is a key aspect in drug discovery for efficacy and safety assessment, in the particular for the translation from the non clinical to the clinical field. Modeling the profile of plasma exposure achieved with the intended therapeutic route often requires the use of intravenous infusion. In addition, in most cases infusion parameters (infusion rate, volume, duration and sequences) need to be customized to achieve the appropriate pattern of plasma drug exposure. When pharmacodynamic parameters are recorded by telemetry, the use of implantable pumps rather than external pumps is necessary to preserve the improvement in physiological data recording offered by telemetry.
  • Part 2: How has HR-MS technology fundamentally changed the way we study drug biotransformation and disposition?
    AB SCIEX is proud to present the 2nd installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 2 of this webinar series will focus on how HRMS technology has fundamentally changed the way metabolite biotransformations are investigated in Lead Discovery.
view more

25 Hottest Articles

view more
Copyright © 2013
Elsevier Ltd. All rights reserved.
Sitemap | Terms & Conditions | Privacy | Cookies | Website Design Working with water